Business
Metagenomi Reports Business Updates and First Quarter 2025 Financial Results
- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile - Well capitalized with $226.0 million in cash, cash equivalents and available-for-sale marketable securities as of March 31, 2025 with runway anticipated to support operations into 2027 EMERYVILLE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medic
About this update from Metagenomi Therapeutics, Inc.
[{"type":"image","alt":"Metagenomi, Inc.","displaySize":"","headline":null,"caption":"Metagenomi, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":120,"url":"https://media.zenfs.com/en/globenewswire.com/f9f4f8ce15a62dc256eccc8b2b88fc5f"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/Ld3K1HIDljOFxzdNkgn1rg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/f9f4f8ce15a62dc256eccc8b2b88fc5f","width":300,"height":120}},"lazy":false},{"type":"text","content":"- Nonhuman primate (NHP) study in hemophilia A demonstrated therapeutically relevant factor VIII (FVIII) activity with durable response through approximately 19 months with an encouraging safety profile","length":202,"tagName":"p"},{"type":"text","content":"- Well capitalized with $226.0 million in cash, cash equivalents and available-for-sale marketable securities as of March 31, 2025 with runway anticipated to support operations into 2027","length":186,"tagName":"p"},{"type":"text","content":"EMERYVILLE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX), a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary gene editing toolbox, today reported financial results for the quarter ended March 31, 2025, and provided business updates.","length":327,"tagName":"p"},{"type":"text","content":"“We are excited about the transformative potential of our AI-driven metagenomics platform across multiple indications in our pipeline,” said Brian C. Thomas, PhD, CEO and founder of Metagenomi. “For our lead program in hemophilia A, we are encouraged by the additional durability of response data demonstrating sustained FVIII activity at therapeutically relevant levels throughout our completed study of approximately 19 months in NHPs. Looking ahead, we plan to leverage these findings to inform the strategy for our MGX-001 program moving forward. Further, we remain well capitalized with cash runway anticipated to support our operations through key milestones into 2027.”","length":676,"tagName":"p"},{"type":"text","content":"First Quarter 2025 Updates","length":26,"tagName":"p"},{"type":"text","content":"Business Updates","length":16,"tagName":"p"},{"type":"text","content":"Hemophilia A Program – approximately 19-month durability results in NHP","lengt...